
Marianne Martinello

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2128469/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	High Effectiveness of Broad Access Directâ€Acting Antiviral Therapy for Hepatitis C in an Australian Realâ€World Cohort: The REACH Study. Hepatology Communications, 2022, 6, 496-512.	2.0	10
2	Maintenance of broad neutralizing antibodies and memory B cells 1 year post-infection is predicted by SARS-CoV-2-specific CD4+ TÂcell responses. Cell Reports, 2022, 38, 110345.	2.9	30
3	Evaluation of the hepatitis C cascade of care among people living with HIV in New South Wales, Australia: A data linkage study. Journal of Viral Hepatitis, 2022, 29, 271-279.	1.0	3
4	Hepatitis C Virus Reinfection Following Direct-Acting Antiviral Treatment in the Prison Setting: The SToP-C Study. Clinical Infectious Diseases, 2022, 75, 1809-1819.	2.9	11
5	Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals. JHEP Reports, 2022, 4, 100462.	2.6	10
6	Persistent highâ€level shedding of cultivable SARSâ€CoVâ€2 Delta virus 33 days after onset of COVIDâ€19 in a hospitalized patient with pneumonia. Journal of Medical Virology, 2022, 94, 4043-4046.	2.5	4
7	Declining prevalence of current HCV infection and increased treatment uptake among people who inject drugs: The ETHOS Engage study. International Journal of Drug Policy, 2022, 105, 103706.	1.6	14
8	Retreatment for hepatitis C virus directâ€acting antiviral therapy virological failure in primary and tertiary settings: The <scp>REACHâ€C</scp> cohort. Journal of Viral Hepatitis, 2022, 29, 661-676.	1.0	7
9	Risk of hepatitis C reinfection following successful therapy among people living with HIV: a global systematic review, meta-analysis, and meta-regression. Lancet HIV,the, 2022, 9, e414-e427.	2.1	23
10	A Testing Campaign Intervention Consisting of Peer-Facilitated Engagement, Point-of-Care HCV RNA Testing, and Linkage to Nursing Support to Enhance Hepatitis C Treatment Uptake among People Who Inject Drugs: The ETHOS Engage Study. Viruses, 2022, 14, 1555.	1.5	7
11	HCV Elimination in Australia. , 2021, , 213-227.		0
12	Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Reports Medicine, 2021, 2, 100228.	3.3	66
13	Opportunities to Enhance Linkage to Hepatitis C Care Among Hospitalized People With Recent Drug Dependence in New South Wales, Australia: A Population-based Linkage Study. Clinical Infectious Diseases, 2021, 73, 2037-2044.	2.9	9
14	Effectiveness of treatment for hepatitis C virus reinfection following direct acting antiviral therapy in the REACH-C cohort. International Journal of Drug Policy, 2021, 96, 103422.	1.6	15
15	Prescribing of directâ€acting antiviral therapy by general practitioners for people with hepatitis C in an unrestricted treatment program. Medical Journal of Australia, 2021, 215, 332-333.	0.8	8
16	Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment ofÂrecently acquired hepatitis C infection. Journal of Hepatology, 2021, 75, 829-839.	1.8	27
17	Progress Towards Elimination of Hepatitis C Infection Among People Who Inject Drugs in Australia: The ETHOS Engage Study. Clinical Infectious Diseases, 2021, 73, e69-e78.	2.9	43
18	Moving Towards Hepatitis C Microelimination Among People Living With Human Immunodeficiency Virus in Australia: The CEASE Study. Clinical Infectious Diseases, 2020, 71, 1502-1510.	2.9	46

#	Article	IF	CITATIONS
19	Shortâ€Duration Panâ€Genotypic Therapy With Glecaprevir/Pibrentasvir for 6 Weeks Among People With Recent Hepatitis C Viral Infection. Hepatology, 2020, 72, 7-18.	3.6	24
20	Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre―and postâ€universal access to directâ€acting antiviral treatment in Australia: The LiveRLife study. Journal of Viral Hepatitis, 2020, 27, 281-293.	1.0	39
21	Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir, a randomised non-inferiority trial. Journal of Hepatology, 2020, 72, 431-440.	1.8	30
22	Association between HTLV-1 infection and adverse health outcomes: a systematic review and meta-analysis of epidemiological studies. Lancet Infectious Diseases, The, 2020, 20, 133-143.	4.6	147
23	Hepatitis C reinfection after successful antiviral treatment among people who inject drugs: A meta-analysis. Journal of Hepatology, 2020, 72, 643-657.	1.8	103
24	Modeling based response guided therapy in subjects with recent hepatitis C infection. Antiviral Research, 2020, 180, 104862.	1.9	6
25	Low hepatitis C virus reinfection rate despite ongoing risk following universal access to direct-acting antiviral therapy among people living with HIV. Aids, 2020, 34, 1347-1358.	1.0	12
26	Hepatitis C elimination in Australia: progress and challenges. Medical Journal of Australia, 2020, 212, 362-363.	0.8	9
27	Progress Toward Hepatitis C Virus Elimination. Gastroenterology Clinics of North America, 2020, 49, 253-277.	1.0	11
28	Transmission of hepatitis C virus in HIVâ€positive and PrEPâ€using MSM in England. Journal of Viral Hepatitis, 2020, 27, 721-730.	1.0	16
29	Global elimination of hepatitis C virus by 2030: why not?. Nature Medicine, 2020, 26, 157-160.	15.2	42
30	Elbasvir and grazoprevir for hepatitis C virus genotype 1 infection in people with recent injecting drug use (DARLOâ€C): An openâ€label, singleâ€arm, phase 4, multicentre trial. Health Science Reports, 2020, 3, e151.	0.6	4
31	Estimated uptake of hepatitis C direct-acting antiviral treatment among individuals with HIV co-infection in Australia: a retrospective cohort study. Sexual Health, 2020, 17, 223.	0.4	8
32	Time to Detection of Hepatitis C Virus Infection With the Xpert HCV Viral Load Fingerstick Point-of-Care Assay: Facilitating a More Rapid Time to Diagnosis. Journal of Infectious Diseases, 2020, 221, 2043-2049.	1.9	16
33	SAT-235-Low HCV reinfection incidence following DAA treatment scale-up in people living with HIV in Australia. Journal of Hepatology, 2019, 70, e734.	1.8	2
34	PS-178-Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study. Journal of Hepatology, 2019, 70, e110.	1.8	2
35	Cure and Control: What Will It Take to Eliminate HCV?. Topics in Medicinal Chemistry, 2019, , 447-490.	0.4	2
36	THU-157-Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvir for six weeks among people with acute and recent HCV infection. Journal of Hepatology, 2019, 70, e231.	1.8	4

#	Article	IF	CITATIONS
37	Hepatitis C virus testing, liver disease assessment and directâ€acting antiviral treatment uptake and outcomes in a service for people who are homeless in Sydney, Australia: The LiveRLife homelessness study. Journal of Viral Hepatitis, 2019, 26, 969-979.	1.0	25
38	A latent class approach to identify multiâ€risk profiles associated with phylogenetic clustering of recent hepatitis C virus infection in Australia and New Zealand from 2004 to 2015. Journal of the International AIDS Society, 2019, 22, e25222.	1.2	6
39	Management of acute HCV in the era of direct-acting antivirals: implications for elimination. The Lancet Gastroenterology and Hepatology, 2019, 4, 256-257.	3.7	5
40	A systematic, deep sequencing-based methodology for identification of mixed-genotype hepatitis C virus infections. Infection, Genetics and Evolution, 2019, 69, 76-84.	1.0	6
41	Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent <scp>HCV</scp> genotype 1 infection. Journal of Viral Hepatitis, 2018, 25, 1180-1188.	1.0	25
42	Uptake of directâ€ e cting antiviral treatment for chronic hepatitis C in Australia. Journal of Viral Hepatitis, 2018, 25, 640-648.	1.0	68
43	Evaluation of the Xpert HCV Viral Load Finger-Stick Point-of-Care Assay. Journal of Infectious Diseases, 2018, 217, 1889-1896.	1.9	88
44	Acceptability and preferences of point-of-care finger-stick whole-blood and venepuncture hepatitis C virus testing among people who inject drugs in Australia. International Journal of Drug Policy, 2018, 61, 23-30.	1.6	57
45	Management of acute HCV infection in the era of direct-acting antiviral therapy. Nature Reviews Gastroenterology and Hepatology, 2018, 15, 412-424.	8.2	62
46	Strategies to Reduce Hepatitis C Virus Reinfection in People Who Inject Drugs. Infectious Disease Clinics of North America, 2018, 32, 371-393.	1.9	27
47	Universal access to DAA therapy paves the way for HCV control and elimination among people living with HIV in Australia. Journal of Hepatology, 2018, 68, S312-S313.	1.8	4
48	Editorial: Observations on the launch of new drugs for hepatitis C. Australian Prescriber, 2018, 41, 4-5.	0.5	10
49	Direct-acting antivirals for acute HCV: how short can we go?. The Lancet Gastroenterology and Hepatology, 2017, 2, 316-318.	3.7	2
50	HCV Cure and Reinfection Among People With HIV/HCV Coinfection and People Who Inject Drugs. Current HIV/AIDS Reports, 2017, 14, 110-121.	1.1	46
51	<scp>HCV</scp> reinfection incidence among individuals treated for recent infection. Journal of Viral Hepatitis, 2017, 24, 359-370.	1.0	68
52	The path towards hepatitis C elimination in Australia following universal access to interferon-free treatments. Journal of Hepatology, 2017, 66, S291-S292.	1.8	8
53	DAA treatment scale-up in HIV/HCV co-infection: characterisinga population at risk for reinfection. Journal of Hepatology, 2017, 66, S495-S496.	1.8	4
54	The Impact of Ribavirin Plasma Concentration on the Efficacy of the Interferon-Sparing Regimen, Sofosbuvir and Ribavirin. Antiviral Therapy, 2016, 21, 127-132.	0.6	3

#	Article	IF	CITATIONS
55	Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range. Infection and Drug Resistance, 2016, 9, 87.	1.1	18
56	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 465-465.	0.6	5
57	Hepatitis C treatment as prevention: evidence, feasibility, and challenges. The Lancet Gastroenterology and Hepatology, 2016, 1, 317-327.	3.7	80
58	Incidence of HCV Reinfection among Treated Individuals with Recently Acquired Infection. Journal of Hepatology, 2016, 64, S620-S621.	1.8	2
59	Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE II study. Hepatology, 2016, 64, 1911-1921.	3.6	50
60	Short Duration Response-Guided Treatment is Effective for Most Individuals with Recent Hepatitis C Infection: The ATAHC II and DARE-C I Studies. Antiviral Therapy, 2016, 21, 425-434.	0.6	6
61	Antiretroviral Use in the CEASE Cohort Study and Implications for Direct-Acting Antiviral Therapy in Human Immunodeficiency Virus/Hepatitis C Virus Coinfection. Open Forum Infectious Diseases, 2016, 3, ofw105.	0.4	16
62	<i>Editorial Commentary</i> : Interferon-free Hepatitis C Treatment Efficacy From Clinical Trials Will Translate to "Real World―Outcomes. Clinical Infectious Diseases, 2016, 62, 927-928.	2.9	5
63	Prevalence and Disease Burden of HCV Coinfection in HIV Cohorts in the Asia Pacific Region: A Systematic Review and Meta-Analysis. AIDS Reviews, 2016, 18, 68-80.	0.5	21
64	Enhancing the detection and management of acute hepatitis C virus infection. International Journal of Drug Policy, 2015, 26, 899-910.	1.6	16
65	What do infectious diseases physicians do? A 2-week snapshot of inpatient consultative activities across Australia, New Zealand and Singapore. Clinical Microbiology and Infection, 2014, 20, 0737-0744.	2.8	17
66	Buruli Ulcer Disease in Travelers and Differentiation of Mycobacterium ulcerans Strains from Northern Australia. Journal of Clinical Microbiology, 2012, 50, 3717-3721.	1.8	10
67	"We are what we eat!―Invasive intestinal mucormycosis: A case report and review of the literature. Medical Mycology Case Reports, 2012, 1, 52-55.	0.7	31